子宫内膜异位症患者腹腔液血管内皮生长因子与内抑素的表达被引量：29

Expression of vascular endothelial growth factor and endostatin in peritoneal fluid of patients with endometriosis

下载PDF

导出

摘要目的探讨子宫内膜异位症(内异症)患者腹腔液中血管内皮生长因子(VEGF)和内抑素(ENS)在内异症血管生成调控机制中的作用。方法采用ELISA法检测50例内异症患者(I～Ⅱ期26例、Ⅲ～Ⅳ期24例)和42例非内异症患者(对照组)腹腔液中VEGF和ENS的含量，分析二者浓度及其比值与内异症之间的关系。结果内异症组腹腔液VEGF、ENS浓度和VEGF／ENS比值均高于对照组(P<0．01)；内异症患者中Ⅲ～Ⅳ期VEGF和ENS含量均高于I～Ⅱ期(P<0．01)，而VEGF／ENS比值前者则低于后者(P<0．01)。增殖期与分泌期比较，除内异症组VEGF水平前者高于后者外(P<0．05)，对照组VEGF和两组ENS水平两期比较均无差异(P>0．05)。结论 VEGF和ENS同时参与了内异症的血管生成调控，而两者表达水平的失衡可能才是内异症发病的关键。 Objective To investigate the r el ationship of vascular endothelial growth factor (VEGF) and endostatin with en-do metriosis. Methods The levels of vascular endothelial growth factor and endostat in were measured using ELISA in 50 women with endometriosis (stage Ⅰ~Ⅱ26 case s and stage Ⅲ~Ⅳ24 cases) in comparison with 42 women without en-dometriosis. R esults The VEGF, endostatin concentrations and VEGF/endostatin ratio in endometr iosis group were signifi-cantly higher than the mean value in the control group (P<0.01). The VEGF and endostatin levels in stages Ⅲand Ⅳwere both significan tly higher than those in stagesⅠandⅡ(397±81 pg/ml vs315±64 pg/ml, 125±62 ng /ml vs66±40 ng/ml, P<0.01). However, the VEGF/endostatin ratio was lower in th e advanced stages. There was no significant difference between follicular phase and luteal phase except that the VEGF level in follicular phase was higher than that in luteal phases. Conclusions Both VEGF and endostatin may play a role in the regulation of angiogenesis of endometriosis, and the balance of angiogenic stimu-lators and inhibitors may be critical to the development of endometriosis.

作者刘木彪何援利彭冬先

机构地区第一军医大学珠江医院妇产科

出处《第一军医大学学报》 CSCD 北大核心 2004年第1期69-71,共3页 Journal of First Military Medical University

基金广东省科技厅科技计划项目(2003B30502)~~

关键词子宫内膜异位症腹腔液血管内皮生长因子内抑素血管生成 endometriosis vascular endothelial growth factor endostatin angioge nesis

分类号 R711.71 [医药卫生—妇产科学]

引文网络
相关文献

参考文献9

1[1]Pepper MS. Manipulating angiogenesis. From basic science to the bedside[J]. Arterioscler Thromb Vasc Biol, 1997, 17(5): 605-19.
2[2]American society for Reproduction Medicine. Revised American society for reproduction medicine classification of endometriosis [J].Fetil Steril, 1997, 67(8): 817-21.
3[3]Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenasis[J]. Am J Pathol, 1995, 146(11): 1029-39.
4[4]Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis [J]. J Biol Chem, 1999, 274(17):11721-6.
5[6]Mclaren J. Vascular endothelial growth factor and endometriotic angiogenesis [ J ]. Hum Reprod Update, 2000, 6(1): 44-5.
6[7]Giudice LC, Tazuke SI, Swiersz LT. Status of current research on endometriosis[J]. J Reprod Med, 1998, 43(3 Suppl): 252-62.
7[9]Kupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis [J]. Hum Reprod Update, 1998, 4(5): 719-23.
8[10]Barcz E, Kaminski P, Marianowski L. VEGF concentration in peritoneal fluid of patients with endometriosis [ J ]. Ginekol Pol, 2001,72(5): 442-8.
9[12]Shaarawy M, E1-Sharkawy SA. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer[J]. Acta Oncol, 2001, 40(4): 513-8.